- Trials with a EudraCT protocol (72)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (9)
72 result(s) found for: Case series.
Displaying page 1 of 4.
EudraCT Number: 2010-022025-15 | Sponsor Protocol Number: 10-2-055 | Start Date*: 2011-02-21 |
Sponsor Name:MUMC | ||
Full Title: Intradiscal Methylene Blue Injection Treatment for Chronic Discogenic Low back pain A prospective Clinical Series followed by a Randomised Placebo-Controlled Clinical Trial | ||
Medical condition: The Randomized Clinical Trial (RCT) aims to prove the hypothesis that Intradiscal Methylene blue Injection is capable of better pain reduction than the best available treatment in patients sufferin... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019945-24 | Sponsor Protocol Number: BEB-10 | Start Date*: 2010-09-24 |
Sponsor Name:Birken GmbH | ||
Full Title: Open, Prospective, Controlled Case series Documentation to Compare Intra-individually the Efficacy and Tolerance of Sericare versus Non-adhesive Wound Dressing alone in Accelerating the Epitheliali... | ||
Medical condition: This is an open, prospective, controlled case-series documentation to compare intra-individually the efficacy and tolerance of Sericare versus standard treatment in accelerating the epithelializati... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004978-27 | Sponsor Protocol Number: 1-2006 | Start Date*: 2007-08-03 |
Sponsor Name:Zentralklinikum St. Pölten | ||
Full Title: Initial Combination of Photodynamic Therapy with Verteporfin and Intravitreal Administration of Ranibizumab in Patients with Subfoveal Choroidal Neovascularisation due to Age-related Macular Degene... | ||
Medical condition: The case-series is designed to evaluate the safety and efficacy of intravitreal ranibizumab used in combination with verteporfin photodynamic therapy (Visudyne) for the treatment of subfoveal CNV s... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005130-12 | Sponsor Protocol Number: 6096A1-007 | Start Date*: 2006-08-03 |
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc | ||
Full Title: A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Rout... | ||
Medical condition: Healthy infants | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-007476-19 | Sponsor Protocol Number: OP/2008/2980 | Start Date*: 2009-09-24 |
Sponsor Name:University Hospitals Bristol NHS Trust | ||
Full Title: A prospective case series of Ranibizumab for the treatment of inflammatory and idiopathic choroidal neovascular membranes. | ||
Medical condition: idiopathic and inflammatory choroidal neovascular membranes | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001685-16 | Sponsor Protocol Number: 6096A1-009 | Start Date*: 2015-04-09 |
Sponsor Name:Wyeth Research Division of Wyeth Pharmceuticals Inc. | ||
Full Title: A Phase 3, Randomized, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Manufactured With and Without Polysorbate 80 in Healt... | ||
Medical condition: Healthy infants | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2005-004770-24 | Sponsor Protocol Number: 6096A1-006 | Start Date*: 2006-08-11 |
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc | ||
Full Title: A Phase 3, Randomized, Active-controlled, Double-Blind Trial of the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumoco... | ||
Medical condition: Healthy infants | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-003224-38 | Sponsor Protocol Number: D4320C00015 | Start Date*: 2007-12-07 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer ... | |||||||||||||
Medical condition: Hormone-refractory prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) GB (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) NL (Prematurely Ended) SE (Completed) FI (Prematurely Ended) PT (Prematurely Ended) HU (Completed) DK (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) IE (Prematurely Ended) LV (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020902-13 | Sponsor Protocol Number: 0001-2010 | Start Date*: 2011-07-22 |
Sponsor Name:Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Innsbruck | ||
Full Title: Intravitreal Lucentis (Ranibizumab) in acute central serous Chrioretinopathy - a prospective, randomized, single blind monocentric study | ||
Medical condition: Acute central serous chorioretinopathy (CSC) CSC is an acute idiopathic chorioretinopathy. While the majority of cases is characterized by a self-limited course, chronic CSC is seen in up to one t... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-003268-19 | Sponsor Protocol Number: BR-TUM-ICG-IV-2 | Start Date*: 2014-10-06 |
Sponsor Name:Jules Bordet Institute | ||
Full Title: Study evaluating breast cancer tumorectomy guided by Near-Infrared imaging after the intravenous injection of free Indocyanine Green | ||
Medical condition: Imaging of tumours and their margins after intravenous injection of Indocyanine Green to breast cancer patients | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002507-15 | Sponsor Protocol Number: GS-US-259-0116 | Start Date*: 2012-06-22 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneo... | |||||||||||||
Medical condition: Coronary artery disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) CZ (Completed) AT (Completed) GB (Completed) BE (Completed) NL (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004455-39 | Sponsor Protocol Number: A3L11 | Start Date*: 2012-04-10 | ||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur S.A | ||||||||||||||||||||||||||||
Full Title: Phase III, randomized, blind-observer, multicenter, four-arm study of three batches of the DTaP-IPV-Hep B-PRP-T vaccine and one arm receiving Infanrix hexa™. | ||||||||||||||||||||||||||||
Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus i... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-002854-25 | Sponsor Protocol Number: CYD65 | Start Date*: 2020-09-13 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3-Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years after the L... | ||
Medical condition: Dengue Fever Dengue Hemorrhagic Fever | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2006-004826-10 | Sponsor Protocol Number: SPRA1002 | Start Date*: 2006-11-02 | |||||||||||
Sponsor Name:Moorfields Eye Hospital | |||||||||||||
Full Title: An observational case series to assess the effects of intravitreal Bevacizumab on eyes with neovascular glaucoma | |||||||||||||
Medical condition: Neovascular Glaucoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014315-12 | Sponsor Protocol Number: LIS143 | Start Date*: 2010-04-08 |
Sponsor Name:CIB/RIVM | ||
Full Title: Immunogenicity of alternate and reduced immunization schedules using the regular thirteen-valent polysaccharide conjugate vaccine against infection with Streptococcus pneumoniae | ||
Medical condition: Immunogenicity of alternate and reduced immunization schedules using the regular thirteen-valent polysaccharide conjugate vaccine against infection with Streptococcus pneumoniae | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003311-19 | Sponsor Protocol Number: AIH-MAB | Start Date*: 2018-01-09 |
Sponsor Name:University Medical Centre Hamburg-Eppendorf | ||
Full Title: Phase IIa proof-of-principle study for the induction treatment of autoimmune hepatitis using infliximab AIH-MAB | ||
Medical condition: Autoimmune Hepatitis (AIH); rare inflammatory liver disease associated with elevated transaminases, elevated Immunoglobulin G, the presence of autoantibodies and interface hepatitis in liver histol... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-002977-33 | Sponsor Protocol Number: Luc01AKSI | Start Date*: 2006-06-22 |
Sponsor Name:University Eye Hospital | ||
Full Title: Safety and efficacy of intravitreal injections of ranibizumab/Lucentis in combination with verteporfin photodynamic therapy (PDT) in patients with choroidal neovascularisation (CNV) secondary to ag... | ||
Medical condition: Age related macular degeneration (AMD) is the leading cause of blindness in individuals older than 50 years in the developed world. Eighty to ninety percent of rapid and severe vision loss due to A... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001042-18 | Sponsor Protocol Number: A3L40 | Start Date*: 2014-08-19 | ||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur SA | ||||||||||||||||||||||||||||
Full Title: This Phase III multi-center study of DTaP-IPV-Hib, with or without Hep B, used as a booster vaccine in healthy infants and toddlers will be conducted with two controlled, blind-observer trial arms ... | ||||||||||||||||||||||||||||
Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus type 1, 2 and 3, prevention against invasive infections caused by Haemophilus in... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) CZ (Completed) ES (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-000477-29 | Sponsor Protocol Number: GPA02 | Start Date*: 2006-05-11 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Safety and immunogenicity of an intramuscular, inactivated, split-virion, pandemic influenza A/H5N1 vaccine in adults and the elderly. | ||
Medical condition: Vaccination of adults (18-60 years) and elderly (>60 years) with pandemic flu H5N1 vaccine. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-004454-26 | Sponsor Protocol Number: A3L10 | Start Date*: 2012-04-10 | ||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur SA | ||||||||||||||||||||||||||||
Full Title: Mono-center, open-label, randomized, active-controlled trial in 310 infants | ||||||||||||||||||||||||||||
Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus i... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
